- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Volume 2009 (2009), Article ID 867678, 13 pages
Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPAR and Identification of TUSC5 Coding Variants in Lean and Obese Humans
1Obesity & Metabolism Research Unit, USDA-Agricultural Research Service Western Human Nutrition Research Center, Davis, CA 95616, USA
2Department of Biological Sciences, Department of Biophysics and Chemical Biology, Seoul National University, Seoul 151-742, South Korea
3Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada K1H 8L1
4Graduate Schools of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan
5Department of Pathology, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60208, USA
6Division of Advanced Therapeutics for Metabolic Diseases, Tohoku University Graduate School of Medicine, Sendai 980-8576, Japan
7Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
8Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
9Institute National de la Santé et de la Recherche Médicale (INSERM) UMR 626, 13385 Marseille and Faculté de Médecine, Université de la Méditerranée, Marseille, France
10Department of Nutrition, University of California, Davis 95616, USA
Received 28 August 2009; Accepted 13 November 2009
Academic Editor: Dipak Panigrahy
Copyright © 2009 Trina A. Knotts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- H. Konishi, M. Sugiyama, K. Mizuno, et al., “Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer,” Oncogene, vol. 22, no. 12, pp. 1892–1905, 2003.
- P. J. Oort, C. H. Warden, T. K. Baumann, T. A. Knotts, and S. H. Adams, “Characterization of Tusc5, an adipocyte gene co-expressed in peripheral neurons,” Molecular and Cellular Endocrinology, vol. 276, no. 1-2, pp. 24–35, 2007.
- G. A. Deblandre, O. P. Marinx, S. S. Evans, et al., “Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth,” The Journal of Biological Chemistry, vol. 270, no. 40, pp. 23860–23866, 1995.
- T. Shibata, H. Koide, R. Hayashi, et al., “Molecular cloning and characterization of rat brain endothelial cell derived gene-1 (tumor suppressor candidate 5) expressing abundantly in adipose tissues,” Molecular and Cellular Endocrinology, vol. 263, no. 1-2, pp. 38–45, 2007.
- H. Koide, T. Shibata, N. Yamada, et al., “Tumor suppressor candidate 5 (TUSC5) is expressed in brown adipocytes,” Biochemical and Biophysical Research Communications, vol. 360, no. 1, pp. 139–145, 2007.
- K. K. Brown, B. R. Henke, S. G. Blanchard, et al., “A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor- reverses the diabetic phenotype of the Zucker diabetic fatty rat,” Diabetes, vol. 48, no. 7, pp. 1415–1424, 1999.
- J. B. Seo, M. J. Noh, E. J. Yoo, et al., “Functional characterization of the human resistin promoter with adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element binding protein 1c and CCAAT enhancer binding protein-,” Molecular Endocrinology, vol. 17, no. 8, pp. 1522–1533, 2003.
- I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith, “The effect of pioglitazone on peroxisome proliferator-activated receptor- target genes related to lipid storage in vivo,” Diabetes Care, vol. 27, no. 7, pp. 1660–1667, 2004.
- G. K. Bandyopadhyay, J. G. Yu, J. Ofrecio, and J. M. Olefsky, “Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects,” Diabetes, vol. 55, no. 8, pp. 2277–2285, 2006.
- J. G. Yu, S. Javorschi, A. L. Hevener, et al., “The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects,” Diabetes, vol. 51, no. 10, pp. 2968–2974, 2002.
- D. D. Sears, G. Hsiao, A. Hsiao, et al., “Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18745–18750, 2009.
- S. Yu, K. Matsusue, P. Kashireddy, et al., “Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor 1 (PPAR1) overexpression,” The Journal of Biological Chemistry, vol. 278, no. 1, pp. 498–505, 2003.
- K. Uno, H. Katagiri, T. Yamada, et al., “Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity,” Science, vol. 312, no. 5780, pp. 1656–1659, 2006.
- K. Tachibana, Y. Kobayashi, T. Tanaka, et al., “Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms,” Nuclear Receptor, vol. 3, article 3, 2005.
- R. Desbriere, V. Vuaroqueaux, V. Achard, et al., “11-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients,” Obesity, vol. 14, no. 5, pp. 794–798, 2006.
- P. J. Oort, T. A. Knotts, M. Grino, et al., “-synuclein is an adipocyte-neuron gene coordinately expressed with leptin and increased in human obesity,” Journal of Nutrition, vol. 138, no. 5, pp. 841–848, 2008.
- N. Ahituv, N. Kavaslar, W. Schackwitz, et al., “A PYY Q62P variant linked to human obesity,” Human Molecular Genetics, vol. 15, no. 3, pp. 387–391, 2006.
- L. Fajas, V. Egler, R. Reiter, et al., “The retinoblastoma-histone deacetylase 3 complex inhibits PPAR and adipocyte differentiation,” Developmental Cell, vol. 3, no. 6, pp. 903–910, 2002.
- R. F. Morrison and S. R. Farmer, “Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis,” The Journal of Biological Chemistry, vol. 274, no. 24, pp. 17088–17097, 1999.
- M. I. Lefterova, Y. Zhang, D. J. Steger, et al., “PPAR and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale,” Genes and Development, vol. 22, no. 21, pp. 2941–2952, 2008.
- M. Schupp, M. I. Lefterova, J. Janke, et al., “Retinol saturase promotes adipogenesis and is downregulated in obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 4, pp. 1105–1110, 2009.
- D. D. Sears, A. Hsiao, J. M. Ofrecio, J. Chapman, W. He, and J. M. Olefsky, “Selective modulation of promoter recruitment and transcriptional activity of PPAR,” Biochemical and Biophysical Research Communications, vol. 364, no. 3, pp. 515–521, 2007.
- J. M. Olefsky, “Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists,” The Journal of Clinical Investigation, vol. 106, no. 4, pp. 467–472, 2000.
- E. J. Yoo, J.-J. Chung, S. S. Choe, K. H. Kim, and J. B. Kim, “Down-regulation of histone deacetylases stimulates adipocyte differentiation,” The Journal of Biological Chemistry, vol. 281, no. 10, pp. 6608–6615, 2006.
- M. Fu, M. Rao, T. Bouras, et al., “Cyclin D1 inhibits peroxisome proliferator-activated receptor -mediated adipogenesis through histone deacetylase recruitment,” The Journal of Biological Chemistry, vol. 280, no. 17, pp. 16934–16941, 2005.
- M. Fu, C. Wang, M. Rao, et al., “Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism,” The Journal of Biological Chemistry, vol. 280, no. 33, pp. 29728–29742, 2005.